PHARMACOKINETICS OF VORICONAZOLE DURING CONTINUOUS VENOVENOUS HEMODIAFILTRATION - Voriconazole during CVVHDF
- Conditions
- Intensive Care Patients with proven or suspected infection with fungal pathogens requiring parenteral therapy with voricaonzole who are undergoing continuous venovenous hemodiafiltration
- Registration Number
- EUCTR2004-003479-35-AT
- Lead Sponsor
- Internal Medicine IV, Mecdical University of Vienna
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 7
Age < 18 years
suspected or proven fungal infection requiring parenteral antifungal therapy with voriconazole
continuous venovenous hemodiafiltration due to acute renal failure
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
requirement of another extracorporal therapy rather than CVVHDF
hypersensitivity or other intolerance to voriconazole
patients receiving terfenadine, astemizole, cisapride, primozide, quinidine, sirolimus, rifampin, rifabutin, efavirenz, carbamazepine, long-acting barbiturates, ritonavir, phenytoin, ergot alkaloids
women of childbearing potential
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method